Plain-English translation of NCT07213791 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Neoplasms research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer treatment called that combines radiation with a targeted approach. The medication is designed to work against cancers that have high levels of a protein called FAP. Researchers want to find the right dose, understand how safe it is, and see how well it works against different types of advanced cancers.
Many advanced cancers are hard to treat with standard therapies, and patients need new options. This medication targets a specific protein found in many solid tumors, offering a potentially new way to attack cancer cells while sparing healthy tissue.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous (IV) infusions of the medication at a hospital or clinic, with doses potentially increasing over time as researchers determine the safest and most effective dose. You will have regular blood tests, imaging scans, and heart monitoring to check for side effects and how well the treatment is working. The study lasts about 5 years total, though the intensity of visits will vary depending on the phase you are in.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States